Axsome Therapeutics Stock News

The second half of 2020 has been pretty dull in terms of AXSM trading relative to the first half. Several positive readouts in H2'20 provided only a modest boost but set the stage for a H1'21 readout

68 % reduction in MADRS Suicidality Item score by Week 1, and 82% reduction by Week 4

R apid and substantial i mprovement in depressive symptoms achieved by 44 % of patients at 2 weeks, 67 % at 6 weeks (MADRS response) , and sustained with long-term treatment

R apid and substantial improvement in depressive symptoms achieved by 40% of patients at 2 weeks, 73% at 6 weeks (MADRS response) , and sustained over 12 months

Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q3 2020 Results - Earnings Call Transcript

Collaboration provides Axsome access to new digital technologies developed by Veeva

NEW YORK, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorder

Axsome to host conference call and webcast on Thursday, November 5, 2020 at 8:00 AM Eastern Time

Harmony Biosciences intends to raise $100 million in an IPO. The firm is developing and commercializing treatments for narcolepsy and related conditions.

Axsome (AXSM) incurs a narrower loss in the second quarter of 2020. The company remains on track to submit the NDA for AXS-05 and AXS-07.

The company announced that it is on track to submit two of its pipeline candidates to the FDA by year-end.

Two NDA submissions, for AXS-05 in MDD and for AXS-07 in migraine, on track for 4Q 2020  Enrollment completed for both the AXS-05 Phase 3 long-term safety trial in MDD, and for the AXS-07 Phase 3 lon

Enrollment complete in the COMET Phase 3 long-term safety trial of AXS-05 in MDD; NDA filing on track for 4Q 2020Results from three Phase 2 open-label efficacy trials of AXS-05 in TRD, antidepressant

Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...

Designation offers potential for expedited development and review FDA Orphan Drug Designation previously granted to Axsome for AXS-12 in narcolepsyThird FDA Breakthrough Therapy designation received